Abbisko Cayman Limited (HKG:2256)
Hong Kong · Delayed Price · Currency is HKD 14.56
+0.60 (4.30%)
Oct 31, 2025, 4:08 PM HKT
Abbisko Cayman Revenue
Abbisko Cayman had revenue of 612.12M CNY in the half year ending June 30, 2025, with 3,111.54% growth. This brings the company's revenue in the last twelve months to 618.84M, up 24.45% year-over-year. In the year 2024, Abbisko Cayman had annual revenue of 503.99M with 2,544.24% growth.
Revenue (ttm)
618.84M CNY
Revenue Growth
+24.45%
P/S Ratio
14.44
Revenue / Employee
2.20M CNY
Employees
281
Market Cap
9.79B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 503.99M | 484.93M | 2,544.24% |
| Dec 31, 2023 | 19.06M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 22.68M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| JD Health International | 71.34B |
| BeOne Medicines AG | 35.81B |
| Sino Biopharmaceutical | 33.49B |
| Alibaba Health Information Technology | 32.81B |
| CSPC Pharmaceutical Group | 28.49B |
| WuXi Biologics | 21.98B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| Innovent Biologics | 12.52B |